CDK4 Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

CDK4 Specific Inhibitors

Product Name	CDK4	CDK1	CDK2	CDK3	CDK5	CDK6	CDK7	CDK9	CDK4 Selectivity	Purity
Palbociclib	Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM					Cdk6/cyclin D2, IC₅₀: 16 nM			Pan Inhibitor	≥95.0%
Palbociclib monohydrochloride	Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM					Cdk6/cyclin D2, IC₅₀: 16 nM			Pan Inhibitor	≥95.0%
Abemaciclib	Cdk4/cyclin D1, IC₅₀: 2 nM	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		CDK5/p35, IC₅₀: 287 nM Cdk5/p25, IC₅₀: 355 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM	CDK9/cyclinT1, IC₅₀: 57 nM	Pan Inhibitor	99.69%
Ribociclib	CDK4, IC₅₀: 10 nM					CDK6, IC₅₀: 39 nM			Pan Inhibitor	99.93%
Abemaciclib methanesulfonate	Cdk4/cyclin D1, IC₅₀: 2 nM	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk5/p25, IC₅₀: 355 nM CDK5/p35, IC₅₀: 287 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM	CDK9/cyclinT1, IC₅₀: 57 nM	Pan Inhibitor	≥98.0%
Flavopiridol	CDK4/Cyc D1, IC₅₀: 100 nM	CDK1/Cyc B1, IC₅₀: 30 nM	CDK2/Cyc E, IC₅₀: 170 nM						Pan Inhibitor	99.72%
PF-06873600	CDK4, Ki: 0.13 nM		CDK2, Ki: 0.09 nM			CDK6, Ki: 0.16 nM			Pan Inhibitor	99.98%
Palbociclib isethionate	Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM					Cdk6/cyclin D2, IC₅₀: 16 nM			Pan Inhibitor	99.96%
SNS-032	CDK4, IC₅₀: 925 nM	CDK1, IC₅₀: 480 nM	CDK2, IC₅₀: 38 nM				CDK7, IC₅₀: 62 nM	CDK9, IC₅₀: 4 nM	Pan Inhibitor	98.50%
AZD-5438	cdk4-cyclin D1, IC₅₀: 449 nM	cdk1-cyclin B1, IC₅₀: 16 nM	cdk2-cyclin E, IC₅₀: 6 nM cdk2-cyclin A, IC₅₀: 45 nM		cdk5-p25, IC₅₀: 14 nM	cdk6-cyclin D3, IC₅₀: 21 nM	cdk7-cyclin H, IC₅₀: 821 nM	cdk9-cyclin T, IC₅₀: 20 nM	Pan Inhibitor	99.37%
AT7519	Cdk4/cyclin D1, IC₅₀: 100 nM	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM	CDK9/Cyclin T, IC₅₀: 10 nM	Pan Inhibitor	99.40%
Flavopiridol Hydrochloride	CDK4/Cyc D1, IC₅₀: 100 nM	CDK1/Cyc B1, IC₅₀: 30 nM	CDK2/Cyc E, IC₅₀: 170 nM						Pan Inhibitor	≥95.0%
GSK 3 Inhibitor IX	Cdk4/cyclin D1, IC₅₀: 10 μM	Cdk1/cyclin B, IC₅₀: 320 nM	cdk2/cyclin A, IC₅₀: 300 nM		CDK5/p35, IC₅₀: 80 nM				Pan Inhibitor	≥98.0%
Ribociclib succinate	CDK4, IC₅₀: 10 nM					CDK6, IC₅₀: 39 nM			Pan Inhibitor	99.52%
JNJ-7706621	Cdk4/cyclin D1, IC₅₀: 253 nM	Cdk1/cyclin B, IC₅₀: 9 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM	CDK3/Cyclin E, IC₅₀: 58 nM		CDK6/cyclinD1, IC₅₀: 175 nM			Pan Inhibitor	99.96%
Samuraciclib hydrochloride	CDK4/Cyc D1, IC₅₀: 49 μM	CDK1/cyc A, IC₅₀: 1.8 μM	cdk2/cyclin A, IC₅₀: 578 nM		CDK5/p35NCK, IC₅₀: 9.4 μM	CDK6/cycD1, IC₅₀: 34 μM	CDK7/cyclin H, IC₅₀: 41 nM	CDK9/CycT1, IC₅₀: 1.2 μM	Pan Inhibitor	99.98%
CVT-313	Cdk4/cyclin D1, IC₅₀: 215 μM	Cdk1/cyclin B, IC₅₀: 4.2 μM	cdk2/cyclin A, IC₅₀: 0.5 μM						Pan Inhibitor	99.76%
CGP60474	CDK4/cyclin D, IC₅₀: 216 nM	CDK1-Cyclin B, IC₅₀: 26 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM		Cdk5/p25, IC₅₀: 10 nM		CDK7/cyclin H, IC₅₀: 200 nM	CDK9/cycT, IC₅₀: 13 nM	Pan Inhibitor	98.70%
Milciclib	cyclin D1/CDK4, IC₅₀: 160 nM	cyclin B/CDK1, IC₅₀: 398 nM	cyclin A/CDK2, IC₅₀: 45 nM cyclin E/CDK2, IC₅₀: 363 nM				cyclin H/CDK7, IC₅₀: 150 nM		Pan Inhibitor	99.92%
BMS-265246	CDK4/cycD, IC₅₀: 230 nM	CDK1/cycB, IC₅₀: 6 nM	CDK2/Cyc E, IC₅₀: 9 nM						Pan Inhibitor	99.28%
R547	CDK4/cyclin D, Ki: 1 nM	Cdk1/cyclin B, Ki: 2 nM Cdk1/cyclin B, IC₅₀: 0.2 nM	CDK2/cyclinE, Ki: 3 nM cdk2/cyclin A, IC₅₀: 0.1 nM CDK2/cyclinE, IC₅₀: 0.4 nM	CDK3/Cyclin E, IC₅₀: 0.8 nM	CDK5/p35, IC₅₀: 0.1 nM	cdk6/cyclin D3, IC₅₀: 4 nM	CDK7/cyclin H, IC₅₀: 171 nM		Pan Inhibitor	99.66%
Ribociclib hydrochloride	CDK4, IC₅₀: 10 nM					CDK6, IC₅₀: 39 nM			Pan Inhibitor	99.95%
LDC000067	cdk4-cyclin D1, IC₅₀: 9242 nM	cdk1-cyclin B1, IC₅₀: 5513 nM	cdk2-cyclin A, IC₅₀: 2441 nM					CDK9- Cyclin T1, IC₅₀: 44 nM	Pan Inhibitor	98.58%
Purvalanol A	cdk4-cyclin D1, IC₅₀: 850 nM	cdc2-cyclin B, IC₅₀: 4 nM	cdk2-cyclin E, IC₅₀: 35 nM cdk2-cyclin A, IC₅₀: 70 nM		cdk5-p35, IC₅₀: 75 nM				Pan Inhibitor	99.11%
Roniciclib	CDK4/cyclin D, IC₅₀: 11 nM	Cdk1/cyclin B, IC₅₀: 7 nM	CDK2/cyclinE, IC₅₀: 9 nM				CDK7/Cyclin H/MAT1, IC₅₀: 25 nM	CDK9/cyclinT1, IC₅₀: 5 nM	Pan Inhibitor	98.89%
Trilaciclib hydrochloride	Cdk4/cyclin D1, IC₅₀: 1 nM					cdk6/cyclin D3, IC₅₀: 4 nM			Pan Inhibitor	99.24%
PHA-793887	Cdk4/cyclin D1, IC₅₀: 62 nM	Cdk1/cyclin B, IC₅₀: 60 nM	cdk2/cyclin A, IC₅₀: 8 nM CDK2/cyclinE, IC₅₀: 8 nM		Cdk5/p25, IC₅₀: 5 nM		CDK7/cyclin H, IC₅₀: 10 nM	CDK9/cyclinT1, IC₅₀: 138 nM	Pan Inhibitor	99.25%
ON123300	Cdk4/cyclin D1, IC₅₀: 3.9 nM					CDK6/cyclinD1, IC₅₀: 9.82 nM			Pan Inhibitor	98.52%
SU9516	CDK4, IC₅₀: 200 nM	CDK1, IC₅₀: 40 nM	CDK2, IC₅₀: 22 nM						Pan Inhibitor	99.83%
BS-181	CDK4/Cyc D1, IC₅₀: 33 μM	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM	CDK9/cycT, IC₅₀: 4.2 μM	Pan Inhibitor	98.10%
FN-1501	Cdk4/cyclin D1, IC₅₀: 0.85 nM		cdk2/cyclin A, IC₅₀: 2.47 nM			CDK6/cyclinD1, IC₅₀: 1.96 nM			Pan Inhibitor	98.41%
Purvalanol B	Cdk4/cyclin D1, IC₅₀: 10000 nM	cdc2/cyclin B, IC₅₀: 6 nM cyclin dependent kinase 1-cyclinB, IC₅₀: 6 nM	cdk2/cyclin A, IC₅₀: 6 nM CDK2/cyclinE, IC₅₀: 9 nM		CDK5/p35, IC₅₀: 6 nM				Pan Inhibitor	≥97.0%
Riviciclib hydrochloride	cdk4-cyclin D1, IC₅₀: 0.063 μM	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.500 μM			cdk6-cyclin D3, IC₅₀: 0.396 μM		CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM	Pan	98.33%
Abemaciclib metabolite M20	CDK4					CDK6			Pan Inhibitor	98.24%
ON-013100	Cdk4/cyclin D1								Pan Inhibitor	98.23%
Abemaciclib metabolite M2	CDK4, IC₅₀: 1-3 nM					CDK6, IC₅₀: 1-3 nM			Pan Inhibitor	99.82%
AT7519 Hydrochloride	Cdk4/cyclin D1, IC₅₀: 100 nM	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM	CDK9/Cyclin T, IC₅₀: 10 nM	Pan Inhibitor	99.99%
CDKI-73	CDK4, IC₅₀: 8.18 nM	CDK1, IC₅₀: 8.17 nM CDK1, Ki: 4 nM	CDK2, IC₅₀: 3.27 nM CDK2, Ki: 3 nM			CDK6, IC₅₀: 37.68 nM	CDK7, IC₅₀: 134.26 nM CDK7, Ki: 91 nM	CDK9, IC₅₀: 5.78 nM CDK9, Ki: 4 nM	Pan Inhibitor	99.58%
AMG 925	CDK4, IC₅₀: 3 nM	CDK1, IC₅₀: 1.9 μM	CDK2, IC₅₀: 375 nM			CDK6, IC₅₀: 8 nM			Pan Inhibitor	99.33%
BS-181 hydrochloride	CDK4/Cyc D1, IC₅₀: 33 μM	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM	CDK9/cycT, IC₅₀: 4.2 μM	Pan Inhibitor	≥99.0%
MC180295	CDK4-Cyclin D, IC₅₀: 112 nM	CDK1-Cyclin B, IC₅₀: 138 nM	cdk2-cyclin A, IC₅₀: 233 nM cdk2-cyclin E, IC₅₀: 367 nM	CDK3-Cyclin E, IC₅₀: 399 nM	cdk5-p35, IC₅₀: 159 nM cdk5-p25, IC₅₀: 186 nM	cdk6-cyclin D3, IC₅₀: 712 nM	CDK7-CycH/MAT1, IC₅₀: 555 nM	CDK9- Cyclin T1, IC₅₀: 5 nM	Pan Inhibitor	98.47%
Voruciclib hydrochloride	CDK4/Cyc D1, Ki: 3.96 nM	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM				CDK6/cycD1, Ki: 2.92 nM		CDK9/CycT1, Ki: 1.68 nM CDK9/cyc T2, Ki: 0.626 nM	Pan Inhibitor	98.20%
Lerociclib dihydrochloride	Cdk4/cyclin D1, IC₅₀: 1 nM	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		CDK5/p35, IC₅₀: 832 nM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM	CDK9/Cyclin T, IC₅₀: 28 nM	Pan Inhibitor	98.45%
Ribociclib succinate hydrate	CDK4, IC₅₀: 10 nM					CDK6, IC₅₀: 39 nM			Pan Inhibitor	99.96%
CDK9-IN-7	CDK4/cyclin D, IC₅₀: 148 nM					CDK6/cyclinD, IC₅₀: 145 nM		CDK9/cyclinT1, IC₅₀: 11 nM	Pan Inhibitor	99.81%
BSJ-04-132	CDK4/D1, IC₅₀: 50.6 nM					CDK6/D1, IC₅₀: 30 nM			Pan Inhibitor	98.08%
BSJ-03-204	CDK4/D1, IC₅₀: 26.9 nM					CDK6/D1, IC₅₀: 10.4 nM			Pan Inhibitor	98.34%
Voruciclib	CDK4/Cyc D1, Ki: 3.96 nM	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM				CDK6/cycD1, Ki: 2.92 nM		CDK9/cyc T2, Ki: 0.626 nM CDK9/CycT1, Ki: 1.68 nM	Pan Inhibitor	99.52%
CAN508	Cdk4/cyclin D1, IC₅₀: 13.5 μM	Cdk1/cyclin B, IC₅₀: 44 μM	CDK2/cyclinE, IC₅₀: 20 μM cdk2/cyclin A, IC₅₀: 69 μM				CDK7/cyclin H, IC₅₀: 26 μM	CDK9/cyclinT1, IC₅₀: 0.35 μM	Pan Inhibitor
NU6140	CDK4-Cyclin D, IC₅₀: 5.5 μM	CDK1-Cyclin B, IC₅₀: 6.6 μM	cdk2-cyclin A, IC₅₀: 0.41 μM		cdk5-p25, IC₅₀: 15 μM		cdk7-cyclin H, IC₅₀: 3.9 μM		Pan Inhibitor	≥99.0%
CDK4/6-IN-2	CDK4, IC₅₀: 2.7 nM					CDK6, IC₅₀: 16 nM			Pan Inhibitor	99.82%
NU6102	CDK4, IC₅₀: 1.6 μM	Cdk1/cyclin B, IC₅₀: 9.5 nM	CDK2/cyclin A3, IC₅₀: 5.4 nM						Pan Inhibitor	≥95.0%
Palbociclib D8	Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM					Cdk6/cyclin D2, IC₅₀: 16 nM			Pan Inhibitor	99.84%
AMG 925 HCl	CDK4, IC₅₀: 3 nM	CDK1, IC₅₀: 1.9 μM	CDK2, IC₅₀: 375 nM			CDK6, IC₅₀: 8 nM			Pan Inhibitor	98.01%
AT7519 trifluoroacetate	Cdk4/cyclin D1, IC₅₀: 100 nM	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM	CDK9/Cyclin T, IC₅₀: 10 nM	Pan Inhibitor	98.16%
CDK4/6-IN-3	CDK4, Ki: 0.3 nM	CDK1, Ki: 110 nM				CDK6, Ki: 2.2 nM			Pan Inhibitor
Riviciclib	cdk4-cyclin D1, IC₅₀: 0.063 μM	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.540 μM			cdk6-cyclin D3, IC₅₀: 0.396 μM		CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM	Pan Inhibitor
Lerociclib	Cdk4/cyclin D1, IC₅₀: 1 nM	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		CDK5/p35, IC₅₀: 0.832 μM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM	CDK9/Cyclin T, IC₅₀: 28 nM	Pan Inhibitor
Nimbolide	CDK4					CDK6			Pan Inhibitor
Indirubin-5-sulfonate	Cdk4/cyclin D1, IC₅₀: 300 nM	Cdk1/cyclin B, IC₅₀: 55 nM	cdk2/cyclin A, IC₅₀: 35 nM CDK2/cyclinE, IC₅₀: 150 nM		CDK5/p35, IC₅₀: 65 nM				Pan Inhibitor
LSN3106729 hydrochloride	CDK4					CDK6			Inhibitor	99.01%

Name
Email *

	Sorry, but the email address you supplied was invalid.